Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) said Friday that a Johns Hopkins doctor cited the clinical feasibility of the company’s VMS+ 3.0 heart analysis system at a cardiovascular imaging conference in Milan.
The Toronto-based medical care device company said in a press release that Dr Shelby Kutty recently gave a presentation on a study of the system at EuroEcho 2018. The study was conducted at the University of Nebraska Medical Center Children's Hospital, according to Ventripoint.
READ: VentriPoint Diagnostics reveals that University of Chicago will assess its heart analysis system
"This study presented at EuroEcho 2018 demonstrates the clinical feasibility of quantifying right and left ventricular volumes and function using VMS+ on two- and three-dimensional images acquired from multiple cardiac ultrasound systems,” Shutty said in a statement.
More than 4,200 people attended the conference, according to Ventripoint.
The response to the system at EuroEcho 2018 indicates a significant need for a cost-effective and accurate approach to volumetric measurements of all four chambers of the heart, according to Mehran Mehrtash, vice president for worldwide distributor sales at Ventripoint.
“The VMS+ technology sets us apart and can make a valuable difference in patient outcomes," Mehrtash said.
The system is not yet available for commercial sale and is for investigational use only, according to Ventripoint.
Shares climbed C$0.01 to C$0.17 in Thursday’s Canadian trading.
Last month, the company told investors that the University of Chicago's medical center was preparing to study the VMS+ system.
Contact Dennis Fitzgerald at [email protected]